Dennis Cho Sells 234 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) insider Dennis Cho sold 234 shares of the company’s stock in a transaction that occurred on Friday, September 20th. The stock was sold at an average price of $46.94, for a total value of $10,983.96. Following the completion of the transaction, the insider now owns 78,393 shares of the company’s stock, valued at $3,679,767.42. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Dennis Cho also recently made the following trade(s):

• On Monday, August 5th, Dennis Cho sold 709 shares of Twist Bioscience stock. The stock was sold at an average price of $39.93, for a total value of $28,310.37.
• On Tuesday, July 2nd, Dennis Cho sold 126 shares of Twist Bioscience stock. The stock was sold at an average price of $48.00, for a total value of $6,048.00.

Twist Bioscience Stock Performance

NASDAQ:TWST opened at $45.67 on Thursday. The stock’s fifty day moving average is $46.59 and its 200 day moving average is $43.22. Twist Bioscience Co. has a fifty-two week low of $14.42 and a fifty-two week high of $60.90. The firm has a market capitalization of $2.68 billion, a PE ratio of -13.59 and a beta of 1.76.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Friday, August 2nd. The company reported ($1.47) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.71). Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. The company had revenue of $81.50 million for the quarter, compared to analysts’ expectations of $77.40 million. During the same quarter in the previous year, the company posted ($1.01) EPS. The business’s quarterly revenue was up 27.7% on a year-over-year basis. Equities analysts forecast that Twist Bioscience Co. will post -3.13 EPS for the current year.

Institutional Trading of Twist Bioscience

Several hedge funds and other institutional investors have recently bought and sold shares of TWST. BNP Paribas Financial Markets lifted its position in shares of Twist Bioscience by 34.8% during the first quarter. BNP Paribas Financial Markets now owns 171,823 shares of the company’s stock worth $5,895,000 after purchasing an additional 44,349 shares during the last quarter. UBS Group AG lifted its position in shares of Twist Bioscience by 106.4% during the fourth quarter. UBS Group AG now owns 213,467 shares of the company’s stock worth $7,868,000 after purchasing an additional 110,036 shares during the last quarter. SageView Advisory Group LLC bought a new stake in shares of Twist Bioscience during the first quarter worth $1,144,000. Susquehanna Fundamental Investments LLC bought a new stake in shares of Twist Bioscience during the first quarter worth $300,000. Finally, Sei Investments Co. lifted its position in shares of Twist Bioscience by 32.7% during the first quarter. Sei Investments Co. now owns 223,555 shares of the company’s stock worth $7,670,000 after purchasing an additional 55,124 shares during the last quarter.

Wall Street Analyst Weigh In

TWST has been the subject of several recent analyst reports. JPMorgan Chase & Co. upped their price target on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research note on Monday, August 5th. TD Cowen increased their target price on Twist Bioscience from $55.00 to $65.00 and gave the company a “buy” rating in a research report on Thursday, June 13th. Barclays lowered their target price on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research report on Monday, August 5th. The Goldman Sachs Group increased their target price on Twist Bioscience from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday, July 9th. Finally, Robert W. Baird increased their target price on Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research report on Monday, August 5th. One investment analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $48.22.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.